- Home
- BIIB vs CCJ Comparison
BIIB vs CCJ Comparison
Compare BIIB & CCJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CCJ
- Stock Information
- Founded
- BIIB 1978
- CCJ 1987
- Country
- BIIB United States
- CCJ Canada
- Employees
- BIIB N/A
- CCJ N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CCJ Other Metals and Minerals
- Sector
- BIIB Health Care
- CCJ Basic Materials
- Exchange
- BIIB Nasdaq
- CCJ Nasdaq
- Market Cap
- BIIB 24.2B
- CCJ 45.6B
- IPO Year
- BIIB 1991
- CCJ N/A
- Fundamental
- Price
- BIIB $182.11
- CCJ $87.60
- Analyst Decision
- BIIB Buy
- CCJ Buy
- Analyst Count
- BIIB 23
- CCJ 6
- Target Price
- BIIB $176.48
- CCJ $114.38
- AVG Volume (30 Days)
- BIIB 2.1M
- CCJ 5.2M
- Earning Date
- BIIB 10-30-2025
- CCJ 11-05-2025
- Dividend Yield
- BIIB N/A
- CCJ 0.13%
- EPS Growth
- BIIB N/A
- CCJ 364.36
- EPS
- BIIB 10.97
- CCJ 0.87
- Revenue
- BIIB $10,065,900,000.00
- CCJ $2,487,042,049.00
- Revenue This Year
- BIIB $2.97
- CCJ $10.98
- Revenue Next Year
- BIIB N/A
- CCJ $4.31
- P/E Ratio
- BIIB $16.58
- CCJ $100.70
- Revenue Growth
- BIIB 4.77
- CCJ 23.88
- 52 Week Low
- BIIB $110.04
- CCJ $35.00
- 52 Week High
- BIIB $185.17
- CCJ $110.16
- Technical
- Relative Strength Index (RSI)
- BIIB 80.52
- CCJ 49.35
- Support Level
- BIIB $165.75
- CCJ $77.70
- Resistance Level
- BIIB $185.17
- CCJ $89.87
- Average True Range (ATR)
- BIIB 5.72
- CCJ 4.59
- MACD
- BIIB 1.79
- CCJ -1.00
- Stochastic Oscillator
- BIIB 91.35
- CCJ 51.56
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About CCJ Cameco Corporation
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. It has three reportable segments, Uranium, Fuel Services, and Westinghouse. It derives maximum revenue from the Westinghouse Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre, and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia, and the United States.